Background: Recognition of HLA alleles is useful in transplantation and in anthropological and disease studies. Acute lymphoblastic leukemia (ALL) is the most common blood cancer. It is now generally agreed that both genetic and environmental factors play an interactive role in the development of ALL disease. It is unknown whether there exists a restriction to certain MHC genotypes in leukemia like ALL.

Methods: Genetic construct of HLA DRB1 was studied in Iranian normal populations and in patients with acute lymphoblastic leukemia using PCR-SSP method.

Results: It was shown that the most common allele in DRB1 locus in normal population was DRB1*11 (20%), whereas DRB1*09 was the least frequent allele (0.9%). Additionally, this study presented the results of HLA-DRB1 typing in 106 ALL patients and compared them with normal individuals. Comparison of the results between the normal population and the patient group revealed that there was allelic association between the DRB1*13 and the disease. Results showed that the difference between the frequencies of DRB1*13 in patients and normal individuals was significant (p=0.04), but there was a moderate difference among the frequencies of DRB1*04, *07, and *09 in childhood (0-15 years) ALL. The frequencies of DRB1*13, *04, and *07 in patients were 2.5, 16, 4.5% and, in normal individuals, were 11.4, 10, and 8.3%, respectively.

Conclusions: It should be concluded that DRB1*13, which showed a decrease in patients, should be protective against acute lymphoblastic leukemia (ALL), whereas DRB1*04, which was moderately increased in patients, could be considered a susceptible allele for childhood ALL.

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.arcmed.2007.09.009DOI Listing

Publication Analysis

Top Keywords

acute lymphoblastic
16
lymphoblastic leukemia
16
normal population
12
normal individuals
12
iranian normal
8
patients acute
8
difference frequencies
8
frequencies drb1*13
8
normal
7
patients
7

Similar Publications

Acute B-lymphoblastic leukemia (B-ALL) is a highly heterogeneous hematologic malignancy, characterized by significant molecular differences among patients as the disease progresses. While the PI3K-Akt signaling pathway and metabolic reprogramming are known to play crucial roles in B-ALL, the interactions between lipid metabolism, immune pathways, and drug resistance remain unclear. In this study, we performed multi-omics analysis on different patient cohorts (newly diagnosed, relapsed, standard-risk, and poor-risk) to investigate the molecular characteristics associated with metabolism, signaling pathways, and immune regulation in B-ALL.

View Article and Find Full Text PDF

Identification of a novel TOP2B::AFF2 fusion gene in B-cell acute lymphoblastic leukemia.

Sci Rep

January 2025

Department of Hematology and Oncology, National Clinical Research Center for Child Health and Disorders, Ministry of Education Key Laboratory of Child Development and Disorders, Chongqing Key Laboratory of Pediatric Metabolism and Inflammatory Diseases, Children's Hospital of Chongqing Medical University, No 136 Zhongshan 2 road, YuZhong district, Chongqing, 400014, China.

Genetic alterations play a pivotal role in leukemic clonal transformation, significantly influencing disease pathogenesis and clinical outcomes. Here, we report a novel fusion gene and investigate its pathogenic role in acute lymphoblastic leukemia (ALL). We engineer a transposon transfection system expressing the TOP2B::AFF2 transcript and introduce it into Ba/F3 cells.

View Article and Find Full Text PDF

Objectives: Acute T-cell lymphoblastic leukemia (T-ALL) is a severe hematologic malignancy with limited treatment options and poor long-term survival. This study explores the role of IKZF1 in regulating BCL-2 expression in T-ALL.

Methods: CUT&Tag and CUT&Run assays were employed to assess IKZF1 binding to the BCL-2 promoter.

View Article and Find Full Text PDF

Acute lymphoblastic leukemia (ALL) is a malignant condition of lymphoid progenitor cells that primarily affects the pediatric population, but also adults. The 5-year survival rate is 90% in children and approximately 40% in adults, with survival increasing through the use of peripheral stem cell allotransplantation (SCT). The relapse rate after stem cell transplantation (SCT) in adult acute lymphoblastic leukemia (ALL) patients ranges from 35% to 45%, making relapse a major cause of death in this population.

View Article and Find Full Text PDF

Acute lymphoblastic leukemia (ALL) is a malignant neoplasm with the highest incidence in the pediatric population. Although the 5-year overall survival is greater than 85%, in emerging countries such as Mexico, the mortality rate is high. In Mexico, B-ALL is the most common type of childhood cancer; different characteristics suggest the presence of the disease; however, the prognosis is dependent on clinical and laboratory features, and no adverse prognostic molecular marker for B-ALL has yet been identified.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!